Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TD

NACompletedINTERVENTIONAL
Enrollment

449

Participants

Timeline

Start Date

November 10, 2015

Primary Completion Date

July 31, 2019

Study Completion Date

December 31, 2019

Conditions
Travelers' DiarrheaFunctional Bowel DisordersReactive Arthritis
Interventions
DRUG

Rifaximin

Rifaximin will be provided to subjects either daily with placebo, or twice daily depending on which of the two experimental arms they are randomized to

DRUG

Placebo

Placebo will be administered twice daily or once daily with rifaximin depending on which experimental arm they are randomized to

Trial Locations (6)

28547

Naval Hospital Camp Lejeune, Marine Corps Base Camp Lejeune

78234

San Antonio Military Medical Center, San Antonio

92134

Naval Medical Center San Diego, San Diego

96786

Tripler Army Medical Center/Schofield Barracks, Honolulu

98431

Madigan Army Medical Center, Tacoma

Unknown

British Army Training Unit Kenya, Nanyuki

Sponsors
All Listed Sponsors
collaborator

Naval Medical Research Center

FED

collaborator

Ministry of Defence, United Kingdom

OTHER_GOV

lead

Henry M. Jackson Foundation for the Advancement of Military Medicine

OTHER

NCT02498301 - Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TD | Biotech Hunter | Biotech Hunter